Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005866 | 1.00 | P2RX7 (0.58) | P2RX7AGTR2EHMT2GRM6HCRTR1 | |
| SCHEMBL311394 | 1.00 | P2RX7 (0.58) | P2RX7AGTR2EHMT2GRM6HCRTR1 | |
| SCHEMBL6179978 | 0.90 | P2RX7 (0.57) | P2RX7AGTR2EHMT2HCRTR1HCRTR2 | |
| SCHEMBL6179972 | 0.90 | P2RX7 (0.57) | P2RX7AGTR2EHMT2HCRTR1HCRTR2 | |
| SCHEMBL3333492 | 0.89 | P2RX7 (0.56) | P2RX7EHMT2HCRTR1HCRTR2MEN1 | |
| SCHEMBL10215490 | 0.89 | P2RX7 (0.56) | P2RX7EHMT2HCRTR1HCRTR2MEN1 | |
| SCHEMBL3337871 | 0.86 | P2RX7 (0.57) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL10270030 | 0.86 | P2RX7 (0.57) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL1177390 | 0.85 | HCRTR1 (0.49) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL2907566 | 0.85 | P2RX7 (0.53) | P2RX7EHMT2HCRTR1HCRTR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102884059-B | N-acyl cyclic amine derivatives or pharmaceutically acceptable salts thereof | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2015-08-26 | — | — | CN | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| CN-104244951-A | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD | 2014-12-24 | — | — | CN | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004054514-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1353918-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-6624164-B2 | Solvates and/or hydrates exhibiting affinity for the arginine-vasopressin V1b receptors or for both V1b and V1a 1a receptors. | SANOFI-SYNTHELABO (FR) | 2003-09-23 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SANOFI-AVENTIS (FR) | 2003-07-24 | — | — | US | disclosed |
| EP-1294700-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002044172-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | AVPR2, AVPR1B, AVPR1A | P2RX7 878/4885AGTR2 36/4885EHMT2 4798/4885 |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, HAMP | P2RX7 3732/4885AGTR2 3531/4885EHMT2 2673/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | P2RX7 3920/4885AGTR2 1604/4885EHMT2 1797/4885 |
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | P2RX7 1641/4885AGTR2 69/4885EHMT2 2190/4885 |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | P2RX7 2991/4885AGTR2 636/4885EHMT2 3681/4885 |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | P2RX7 317/4885AGTR2 227/4885EHMT2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.